Abstract Body

Background

Despite achieving sustained virologic response (SVR) with direct-acting antivirals (DAA), individuals HCV/HIV+ with cirrhosis remain at risk of developing hepatocellular carcinoma (HCC). Identifying biomarkers that anticipate HCC onset is therefore crucial. We have previously reported that plasma extracellular vesicles (pEV) from individuals HCV/HIV+ who later developed HCC downmodulate NK cell function. The aim of this study was to define the underlying mechanisms contributing to immune evasion and tumor development, focusing on PD-L1 carried by pEV as a potential target for early detection and prevention.

Methods

Plasma samples were collected after SVR from HCV/HIV+ individuals with mild (METAVIR F0/F1, n=4) and advanced liver disease (METAVIR F4, n=9) following DAA therapy. Notably, four participants with cirrhosis who later developed HCC — a median of 7.00 years (IQR 4.67–7.96) after achieving viral clearance — had available plasma samples collected prior to their cancer diagnosis, providing a unique opportunity to identify early plasma signatures linked to HCC emergence. The pEV were isolated by size exclusion chromatography from 2 mL of plasma and captured overnight with anti-CD9–coupled beads and stained with anti-CD9, anti–PD-1, or anti–PD-L1 antibodies. Expression of markers on pEV was analyzed by flow cytometry.

Results

At 12 months post-SVR, PD-L1 expression on pEV was low across all groups: 6.53% (IQR 6.00–8.70) in F0/F1, 1.70% in F4 without HCC, and 2.68% (IQR 1.12–2.94) in F4 with HCC. Importantly, longitudinal samples available from F4 individuals who later developed HCC revealed a marked rise in PD-L1 expression at later post-SVR intervals (40–90 months), reaching 23.30% (IQR 17.10–29.50) at least 5-8 months prior to HCC suspicions. This increase was not observed in  individuals with cirrhosis who did not develop HCC, underscoring the potential of pEV-associated PD-L1 as an early indicator of hepatocarcinogenesis.

Conclusions

PD-L1 expression on pEV is low at early post-SVR time points but increases over time in individuals with cirrhosis who subsequently develop HCC, suggesting its potential value as an early biomarker of hepatocarcinogenesis. The availability of longitudinal plasma samples obtained years before HCC diagnosis provides unique evidence supporting the role of PD-L1 as a predictive marker. Monitoring PD-L1 on pEVs may therefore support risk stratification for HCC development and inform differential surveillance strategies focused on high-risk individuals.